Truist Financial Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS - Get Free Report) had its price target reduced by equities research analysts at Truist Financial from $100.00 to $43.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's price target would indicate a potential upside of 151.17% from the company's previous close.

A number of other equities analysts have also recently commented on KROS. HC Wainwright reduced their price target on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a report on Friday, December 13th. BTIG Research lowered Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, December 12th. William Blair downgraded Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating on the stock. Finally, Guggenheim lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday, December 16th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Keros Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $75.00.

Keros Therapeutics Trading Up 0.5 %

Shares of Keros Therapeutics stock traded up $0.09 during trading hours on Monday, reaching $17.12. 974,212 shares of the company's stock were exchanged, compared to its average volume of 489,336. The stock has a market cap of $693.48 million, a P/E ratio of -3.29 and a beta of 1.20. The company has a 50 day moving average of $54.97 and a two-hundred day moving average of $51.62. Keros Therapeutics has a fifty-two week low of $15.67 and a fifty-two week high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same quarter last year, the firm posted ($1.33) EPS. The company's revenue was up 4750.0% compared to the same quarter last year. As a group, analysts expect that Keros Therapeutics will post -5.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KROS. KBC Group NV grew its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after purchasing an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics in the 2nd quarter valued at about $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the 3rd quarter valued at approximately $213,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.